Table V.

Odds Ratios of Outcome by Gestational Age and Antenatal Corticosteroid and Magnesium Sulfate Exposure^*

Outcome	Antenatal Corticosteroids + Magnesium Sulfate (vs. Antenatal Corticosteroids Only)		Antenatal Corticosteroids + Magnesium Sulfate (vs. Magnesium Sulfate Only)		Antenatal Corticosteroids + Magnesium Sulfate (vs. No Antenatal Corticosteroids or Magnesium Sulfate)
	Unadjusted OR (CI)	Adjusted OR (CI)*	Unadjusted OR (CI)	Adjusted OR (CI)*	Unadjusted OR (CI)	Adjusted OR (CI)*
22–24 Weeks’ Gestation
Severe NDI‡ or death†	0.79 (0.58, 1.08)	0.81 (0.58, 1.12)	0.2 (0.08, 0.5)	0.21 (0.08, 0.58)	0.48 (0.31, 0.74)	0.61 (0.39, 0.97)
Severe NDI†‡	0.96 (0.62, 1.48)	0.98 (0.61, 1.55)	0.2 (0.07, 0.56)	0.19 (0.06, 0.60)	0.88 (0.46, 1.69)	1.01 (0.51, 2.00)
25–26 Weeks’ Gestation
Severe NDI‡ or death†	0.66 (0.5, 0.87)	0.67 (0.49, 0.90)	0.76 (0.41, 1.43)	0.70 (0.36, 1.36)	0.73 (0.5, 1.07)	0.70 (0.47, 1.06)
Severe NDI†‡	0.74 (0.5, 1.1)	0.69 (0.46, 1.03)	1.19 (0.43, 3.29)	1.00 (0.36, 2.81)	1.1 (0.6, 2.02)	0.93 (0.50, 1.73)

NDI, neurodevelopmental impairment.

^*All models were simultaneously adjusted for: gestational age (square root transformation), sex, small for gestational age, maternal health insurance status, maternal race, follow-up window, and center (as a random effect). Centers with low frequencies of severe cerebral palsy (n<5) were pooled to counter the effects of small sample sizes. Outcome differences statistically significant if adjusted odds ratios between exposure groups exclude 1.

^†Significant global test for differences among groups: (1) ANS and MgSO4, (2) ANS only, (3) antenatal MgSO4 only, and (4) no ANS or MgSO4

^‡Severe neurodevelopmental impairment defined as ≥ 1 of the following: severe cerebral palsy, gross motor function level ≥ 4–5, motor and/or cognitive composite score < 70 on Bayley Scales of Infant Development III, bilateral blindness (no useful vision in either eye), or bilateral hearing impairment even with amplification.